<DOC>
	<DOCNO>NCT00529360</DOCNO>
	<brief_summary>Hypothesis : Myeloablative conditioning use dose escalation clofarabine combination cytarabine ( ARA-C ) total body irradiation ( TBI ) lead improve survival previously untransplanted child adolescent acute lymphoblastic leukemia ( ALL ) acute non-lymphoblastic leukemia ( ANLL ) follow allogeneic stem cell transplantation ( AlloSCT ) .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplant With Clofarabine , Ara-C TBI AML ALL</brief_title>
	<detailed_description>Pediatric patient ALL multiple relapse show decline reinduction rate successive relapse . Chessels et al report result 235 pediatric patient ALL CR3 treat 1972 1998 . Only 18 235 patient remain alive , multiple early treatment failure imply significant instability third remission state . Factors find significant influence survival patient CR3 length CR2 , type second event , immunophenotype , type third treatment , type first relapse , present leukocyte count , length CR1 . The 3-year leukemia-free survival patient ALL CR3 treat hematopoietic progenitor cell transplantation ( HPCT ) report 20 % single-institution report patient transplant unrelated donor 1987 1999 . This report find 20 % relapse rate ALL patient CR3 report patient transplanted 1992 high rate relapse , imply improve chemotherapy regimens become successful curing patient , develop relapse may disease resistant treatment . Clofarabine ( [ 2-chloro-9- ( 2-deoxy-2-fluoro-D-arabinofuranosyl ) adenine ] ; Cl-F-ara-A ; CAFdA ) rationally design , second-generation purine nucleoside antimetabolite . Clofarabine design hybrid molecule overcome limitation incorporate best quality fludarabine ( F-ara-A ) cladribine ( 2-CdA , CdA ) , three molecule currently approve FDA treatment hematologic malignancy . In open-label Phase II , pediatric patient refractory relapse ALL receive clofarabine 52 mg/m2 IVI 2 hour 5 consecutive day repeat every 2 6 week depend toxicity response . Among 49 patient evaluated efficacy , overall remission rate 20 % . The median duration remission could calculate 6 patient achieve CR 3 patient still remission time data cutoff . The median duration 4 patient achieve CRp 20 week ( Range : 4.6 28.6 week ) . Eight ( 16 % ) patient go receive transplant 7 ( 14 % ) experience clinical benefit . In open-label Phase II study , pediatric patient refractory relapse AML receive clofarabine 52 mg/m2 IVI 2 hour 5 consecutive day repeat every 2 6 week depend toxicity response . The overall remission rate ( CR + CRp ) 3 % ; 23 % patient achieve PR . The median duration remission patient achieve least PR 16.2 week . Twelve ( 34 % ) patient go receive transplant , 7 still alive time data cutoff survival range 16.4 week 93.6 week . Patients enrol must undergo extensive pre-transplant evaluation ass remission status , assure adequate organ system function , document freedom active viral , bacterial , fungal infection . Patients proceed transplant soon possible follow reinduction chemotherapy . Patients delays therapy due toxicity donor procurement delay receive maintenance chemotherapy possible . Patients must schedule begin preparative regimen within 10 day enrol study . This 2 part study . Part A dose escalation phase . Once MTD and/or safe/tolerated dose clofarabine establish , Part B accrue patient define event free , disease free overall survival MTD safe/tolerated dose clofarabine . At study entry Part A , clofarabine dose level assign patient . During Part B , establish MTD safe/tolerated dose clofarabine use . In Part A study enroll patient ALL ANLL relapse , induction failure , CR3 CR3P without prior AlloSCT . These patient receive condition regimen clofarabine , ARA-C TBI follow AlloSCT . Patients start pre-conditioning regimen Day -10 . Patients receive ARA-C ( 3000 mg/m2 [ total ARA-C dose 18g/m2 ] ) daily Days -10 , -9 , -8 , -7 , -6 , -5 clofarabine ( Dose assign enrollment , see section 8.2.2 dose escalation table Part A ) Days -9 , -8 , -7 , -6 , -5 . On day clofarabine ARA-C give , clofarabine give 2 hr infusion follow 4 hr rest ARA-C give 3 hr infusion . Fractionated TBI ( 200 cGy ) administer twice daily 3 day Day -4 , -3 -2 . The AlloSCT perform Day 0 . GVHD prophylaxis consist tacrolimus MMF . In Part B , study enroll patient ALL ANLL CR3 CR3P without prior AlloSCT . The pre-conditioning regimen Part A EXCEPT establish MTD safe/tolerated dose clofarabine Part A utilized .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Age : Patients must &lt; 30 year age . Disease Status : ALL relapse , induction failure , CR3 , CR3P ( Part A ONLY ) ; AML relapse , induction failure , CR3 , CR3P ( Part A ONLY ) ; ALL CR3 CR3P ( Part A Part B ) ; AML CR3 CR3P ( Part A BONLY ) ; CR3/CR3P must document bone marrow CNS assessment within 14 day initiation pretransplant conditioning regimen . Creatinine clearance &gt; 40 ml/min/m2 &gt; 60 ml/min/1.73 m2 equivalent radioisotope glomerular filtration rate ( GFR ) determine institutional normal range serum creatinine base age Adequate liver function define : Total bilirubin &lt; 2.5 mg/dl l , SGOT ( AST ) SGPT ( ALT ) &lt; 5 x upper limit normal Adequate cardiac function define : Shortening fraction &gt; 27 % echocardiogram , Ejection fraction &gt; 50 % radionuclide angiogram echocardiogram . Adequate pulmonary function define : Corrected DLCO &gt; 60 % pulmonary function test ; For child uncooperative , evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % room air . Performance Status : For patient age 116 year , Lansky score &gt; 60 ; For patient &gt; 16 year , Karnofsky score &gt; 60 . Patients must receive minimum one round reinduction one round consolidation chemotherapy relapse # 2 Patients prior myeloablative allogeneic stem cell transplantation /or TBI . Females pregnant ( positive HCG ) lactating . Karnofsky &lt; 60 % Lansky &lt; 60 % less 16 year age Age &gt; 30 year age Any patient uncontrolled infection prior study entry Patients evidence active disease . Patients Down syndrome excluded</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute Leukemia</keyword>
	<keyword>Allogeneic Stem Cell Transplant</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
</DOC>